BPC-157 + TB-500 5mg+5mg Dosage Protocol

1. Preparation and Measurement

BPC-157 + TB-500 5mg+5mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

Preparation

1. Draw 2mL of bacteriostatic water using sterile equipment.
2. Let the liquid run slowly down the inside wall of the vial.
3. Gently swirl until dissolved. Do not shake.
4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Vial estimate: One 10mg vial contains approximately 20 administrations at the first listed amount or 10 at the final listed amount.

Practical Notes

• The table applies only to this vial prepared with exactly 2mL.
• The vial contains 5mg BPC-157 + 5mg TB-500; all measurements preserve that fixed component ratio.
• Record the amount, date, and preparation used.

3. Supplies Needed

• BPC-157 + TB-500 5mg+5mg vial.
• 2mL of bacteriostatic water per vial.
• Sterile U-100 syringes.
• Alcohol swabs.
• Sharps container.

4. Storage and Handling

• Keep unopened vials cool, dry, dark, and protected from moisture.
• After preparation, refrigerate at 2-8 degrees C.
• Protect from light and avoid repeated freeze-thaw cycles.
• Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

BPC-157 and thymosin-related peptides have separate preclinical research histories, but the exact combined vial has not been validated in controlled human trials.

The blend is not an approved therapeutic drug. Findings for either component alone cannot establish the safety, efficacy, or interaction profile of the combination.

Primary Research and Regulatory References

1. Thymosin beta-4 wound-healing research
2. Thymosin beta-4 cell-migration study
3. BPC-157 rat Achilles tendon study
4. FDA: BPC-157 compounding and safety concerns